S&P 500   5,120.45 (-1.51%)
DOW   37,952.61 (-1.32%)
QQQ   437.48 (-1.77%)
AAPL   176.11 (+0.61%)
MSFT   421.86 (-1.42%)
META   510.81 (-2.36%)
GOOGL   157.35 (-1.29%)
AMZN   185.45 (-1.90%)
TSLA   171.18 (-1.96%)
NVDA   882.03 (-2.66%)
AMD   163.18 (-4.29%)
NIO   4.14 (-7.17%)
BABA   71.57 (-4.38%)
T   16.30 (-0.73%)
F   12.51 (-4.06%)
MU   122.04 (-4.29%)
GE   154.45 (-1.87%)
CGC   7.72 (-5.28%)
DIS   114.04 (-2.65%)
AMC   2.65 (-5.36%)
PFE   25.91 (-1.63%)
PYPL   64.35 (-2.20%)
XOM   120.08 (-1.40%)
S&P 500   5,120.45 (-1.51%)
DOW   37,952.61 (-1.32%)
QQQ   437.48 (-1.77%)
AAPL   176.11 (+0.61%)
MSFT   421.86 (-1.42%)
META   510.81 (-2.36%)
GOOGL   157.35 (-1.29%)
AMZN   185.45 (-1.90%)
TSLA   171.18 (-1.96%)
NVDA   882.03 (-2.66%)
AMD   163.18 (-4.29%)
NIO   4.14 (-7.17%)
BABA   71.57 (-4.38%)
T   16.30 (-0.73%)
F   12.51 (-4.06%)
MU   122.04 (-4.29%)
GE   154.45 (-1.87%)
CGC   7.72 (-5.28%)
DIS   114.04 (-2.65%)
AMC   2.65 (-5.36%)
PFE   25.91 (-1.63%)
PYPL   64.35 (-2.20%)
XOM   120.08 (-1.40%)
S&P 500   5,120.45 (-1.51%)
DOW   37,952.61 (-1.32%)
QQQ   437.48 (-1.77%)
AAPL   176.11 (+0.61%)
MSFT   421.86 (-1.42%)
META   510.81 (-2.36%)
GOOGL   157.35 (-1.29%)
AMZN   185.45 (-1.90%)
TSLA   171.18 (-1.96%)
NVDA   882.03 (-2.66%)
AMD   163.18 (-4.29%)
NIO   4.14 (-7.17%)
BABA   71.57 (-4.38%)
T   16.30 (-0.73%)
F   12.51 (-4.06%)
MU   122.04 (-4.29%)
GE   154.45 (-1.87%)
CGC   7.72 (-5.28%)
DIS   114.04 (-2.65%)
AMC   2.65 (-5.36%)
PFE   25.91 (-1.63%)
PYPL   64.35 (-2.20%)
XOM   120.08 (-1.40%)
S&P 500   5,120.45 (-1.51%)
DOW   37,952.61 (-1.32%)
QQQ   437.48 (-1.77%)
AAPL   176.11 (+0.61%)
MSFT   421.86 (-1.42%)
META   510.81 (-2.36%)
GOOGL   157.35 (-1.29%)
AMZN   185.45 (-1.90%)
TSLA   171.18 (-1.96%)
NVDA   882.03 (-2.66%)
AMD   163.18 (-4.29%)
NIO   4.14 (-7.17%)
BABA   71.57 (-4.38%)
T   16.30 (-0.73%)
F   12.51 (-4.06%)
MU   122.04 (-4.29%)
GE   154.45 (-1.87%)
CGC   7.72 (-5.28%)
DIS   114.04 (-2.65%)
AMC   2.65 (-5.36%)
PFE   25.91 (-1.63%)
PYPL   64.35 (-2.20%)
XOM   120.08 (-1.40%)
NASDAQ:MDWD

MediWound (MDWD) Stock Price, News & Analysis

$15.84
-0.01 (-0.06%)
(As of 03:34 PM ET)
Today's Range
$15.52
$15.98
50-Day Range
$11.25
$17.11
52-Week Range
$7.10
$17.25
Volume
52,861 shs
Average Volume
65,142 shs
Market Capitalization
$150.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.00

MediWound MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
102.0% Upside
$32.00 Price Target
Short Interest
Healthy
2.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.98mentions of MediWound in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.93) to ($1.86) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.08 out of 5 stars

Medical Sector

1732nd out of 2,784 stocks

Medicinals & Botanicals Industry

13th out of 33 stocks

MDWD stock logo

About MediWound Stock (NASDAQ:MDWD)

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

MDWD Stock Price History

MDWD Stock News Headlines

Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
MediWound: Q4 Earnings Snapshot
MediWound Q4 2023 Earnings Preview
MediWound Shares Climb on Positive Data for EscharEx
See More Headlines
Receive MDWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/21/2023
Today
4/12/2024
Next Earnings (Estimated)
6/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medicinals & botanicals
Sub-Industry
N/A
Current Symbol
NASDAQ:MDWD
Employees
100
Year Founded
2001

Price Target and Rating

Average Stock Price Target
$32.00
High Stock Price Target
$36.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+101.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-6,720,000.00
Pretax Margin
-34.95%

Debt

Sales & Book Value

Annual Sales
$18.69 million
Book Value
$3.43 per share

Miscellaneous

Free Float
8,619,000
Market Cap
$150.42 million
Optionable
Optionable
Beta
0.93

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Ms. Hani Luxenburg (Age 51)
    Chief Financial Officer
    Comp: $235k
  • Mr. Ofer Gonen B.Sc. (Age 51)
    Chief Executive Officer
    Comp: $485k
  • Dr. Lior Rosenberg M.D. (Age 78)
    Co-Founder
    Comp: $727k
  • Dr. Shmulik Hess Ph.D. (Age 51)
    COO & Chief Commercial Officer
  • Mr. Yaron Meyer Adv. (Age 45)
    Executive VP, General Counsel & Corporate Secretary
    Comp: $240k
  • Mr. Barry J. Wolfenson (Age 57)
    Executive Vice President of Strategy & Corporate Development
  • Dr. Ety Klinger MBA (Age 62)
    Ph.D., Chief Research & Development Officer
    Comp: $393k
  • Dr. Robert J. Snyder CWS (Age 74)
    D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc., Chief Medical Officer

MDWD Stock Analysis - Frequently Asked Questions

Should I buy or sell MediWound stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MDWD shares.
View MDWD analyst ratings
or view top-rated stocks.

What is MediWound's stock price target for 2024?

2 analysts have issued 12 month price objectives for MediWound's shares. Their MDWD share price targets range from $28.00 to $36.00. On average, they anticipate the company's share price to reach $32.00 in the next twelve months. This suggests a possible upside of 102.0% from the stock's current price.
View analysts price targets for MDWD
or view top-rated stocks among Wall Street analysts.

How have MDWD shares performed in 2024?

MediWound's stock was trading at $10.17 at the start of the year. Since then, MDWD shares have increased by 55.8% and is now trading at $15.84.
View the best growth stocks for 2024 here
.

When is MediWound's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 4th 2024.
View our MDWD earnings forecast
.

How were MediWound's earnings last quarter?

MediWound Ltd. (NASDAQ:MDWD) released its earnings results on Tuesday, November, 21st. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.45) by $0.21. The biopharmaceutical company had revenue of $4.78 million for the quarter, compared to analysts' expectations of $4.73 million. MediWound had a negative trailing twelve-month return on equity of 20.22% and a negative net margin of 35.94%. During the same quarter in the previous year, the company posted ($0.91) earnings per share.

When did MediWound's stock split?

MediWound shares reverse split before market open on Tuesday, December 20th 2022. The 1-7 reverse split was announced on Tuesday, December 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What other stocks do shareholders of MediWound own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), Blackstone (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC).

Who are MediWound's major shareholders?

MediWound's stock is owned by a variety of institutional and retail investors. Top institutional investors include Silverberg Bernstein Capital Management LLC (0.90%).

How do I buy shares of MediWound?

Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MDWD) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners